menu
    • menu
    [{"orgOrder":0,"company":"Conduit Pharma","sponsor":"Murphy Canyon Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2022","type":"Private Placement","leadProduct":"AZD5904","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Conduit Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Conduit Pharma \/ Murphy Canyon Acquisition Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Conduit Pharma \/ Murphy Canyon Acquisition Corp."},{"orgOrder":0,"company":"Conduit Pharma","sponsor":"Murphy Canyon Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Merger","leadProduct":"AZD5904","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Conduit Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Conduit Pharma \/ Murphy Canyon Acquisition","highestDevelopmentStatusID":"8","companyTruncated":"Conduit Pharma \/ Murphy Canyon Acquisition"}]

    Find Clinical Drug Pipeline Developments & Deals for AZD5904

    Menu

    AZD5904

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Conduit Pharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Conduit Pharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZD5904

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Murphy Canyon Acquisition

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination

                            Details : The combined company will accelerate development of Conduit’s autoimmune disease and idiopathic male infertility pipeline, including AZD5904, a potent orally bioavailable MPO inhibitor.

                            Brand Name : AZD5904

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 22, 2023

                            Lead Product(s) : AZD5904

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Murphy Canyon Acquisition

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Conduit Pharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Conduit Pharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZD5904

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Murphy Canyon Acquisition Corp.

                            Deal Size : $27.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Conduit Pharmaceuticals to Become a Publicly Traded Company via Merger with Murphy Canyon Acquisition Corp.

                            Details : AZD5904 is a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

                            Brand Name : AZD5904

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 09, 2022

                            Lead Product(s) : AZD5904

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Murphy Canyon Acquisition Corp.

                            Deal Size : $27.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth